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English abstract 
 
     This is a descriptive clinical study compiled at Al Shaab Teaching 
Hospital, Khartoum, Sudan, with Department of Internal Medicine –
Khartoum University on 100 patients during the period from February 
2002 to October 2004. The objective of this study was to identify the 
prevalence of the neurological complications of diabetic patients 
attending the outpatient clinics of Al Shaab Teaching Hospital in 
Khartoum.. One hundred cases of diabetes mellitus (DM) were studied 
for prevalence of neurological manifestations, they were 62 male and 38 
females. More than 85% were above the age of 35 years and 56% were in 
the age group 35- 64. The patients were from different tribes and different 
states.  
               This study revealed that 60% of the diabetic patients examined 
have neurological manifestations. The main neurological complication is 
peripheral sensori-motor neuropathy. Diabetic amyotrophy was found in 
8% of patients  
             There was a significant positive correlation between age, duration 
of diabetes, glycaemic control and occurrence of the neurological 
complications.  
              60% of the patients of diabetes mellitus with neurological 
manifestations were of Northern Sudanese origin while the rest of 
patients were from eastern and western states. 83.7% of the patients were 
type 1 diabetes mellitus and 78.4% of them have diabetes for one year or 
more duration. Hypertension was found to be associated with diabetes 
mellitus. in 28% of patients    
 
  
 
  
 
 
    
  ﻣﻮﺟﺰ اﻟﺪراﺳﺔ
  
 اﻟѧﺴﻮدان - اﻟﺒﺎﻃﻨﻴﺔ ﺑﻤﺪﻳﻨﺔ اﻟﺨﺮﻃﻮم اﻷﻣﺮاضﺗﻤﺖ هﺬﻩ اﻟﺪراﺳﺔ ﺑﻤﺴﺘﺸﻔﻲ اﻟﺸﻌﺐ اﻟﺘﻌﻠﻴﻤﻲ ﻗﺴﻢ 
   .4002 اﻟﻲ اآﺘﻮﺑﺮ 2002 ﺣﺎﻟﺔ ﺑﺎﻟﻔﺘﺮة ﻣﻦ ﻓﺒﺮاﻳﺮ 001ﻋﻠﻲ 
اﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ اﻟﺘﻌﺮف ﻋﻠﻲ ﻣﻌѧﺪﻻت ﺣѧﺪوث اﻟﻤѧﻀﺎﻋﻔﺎت اﻟﺘѧﻲ ﻳѧﺼﻴﺐ اﻟﺠﻬѧﺎز اﻟﻌѧﺼﺒﻲ 
ﻳﻌﺮﺿѧﻮن ﻋﻠѧﻲ اﻟﻌﻴѧﺎدة اﻟﻤﺤﻮﻟѧﺔ ﺑﻤﺴﺘѧﺸﻔﻲ اﻟѧﺸﻌﺐ اﻟﺘﻌﻠﻴﻤѧﻲ ﻗѧﺴﻢ ﻟﻤﺮﺿﻲ اﻟﺪاء اﻟﺴﻜﺮي اﻟﻠѧﺬﻳﻦ 
  . اﻟﺴﻮدان-اﻻﻣﺮاض اﻟﺒﺎﻃﻨﻴﺔ ﺑﻤﺪﻳﻨﺔ اﻟﺨﺮﻃﻮم
 ﺣﺎﻟѧﺔ داء ﺳѧﻜﺮي 001ﺗﻌﺘﺒﺮ اﻟﺪراﺳﺔ وﺻﻔﻴﺔ ﺳﺮﻳﺮﻳﺔ، ﺗﻢ ﻓﻴﻬﺎ دراﺳﺔ اﻟﻤﻀﺎﻋﻔﺎت اﻟﻌѧﺼﺒﻴﺔ ﻓѧﻲ 
  .او دﻻﻻت ﻋﺼﺒﻴﺔ/ ﻟﺪﻳﻬﺎ اﻋﺮاض و
ﻣﺜﻠѧﺖ ﻣﻌѧﺪﻻت ﺣѧﺪوث اﻟﻤѧﻀﺎﻋﻔﺎت اﻟﺘѧﻲ ﺗﺒﻴﻦ ﻣﻦ اﻟﺪراﺳﺔ ان اﻏﻠѧﺐ اﻟﻤѧﺼﺎﺑﻴﻦ ﻣѧﻦ اﻟѧﺬآﻮر ﺣﻴѧﺚ 
، آﺎﻧѧﺖ اﻟﻔﺌѧﺔ اﻟﻌﻤﺮﻳѧﺔ ﻟﻤﺠﻤﻮﻋѧﺔ %83ﺑﻴﻨﻤѧﺎ ﻣﺜﻠѧﺖ اﻻﻧѧﺎث % 26ﻳﺼﻴﺐ اﻟﺠﻬﺎز اﻟﻌﺼﺒﻲ ﻟѧﺪﻳﻬﻢ 
  %.65 ﺳﻨﺔ هﻲ اﻻآﺜﺮ ﺗﺄﺛﺮا ﺣﻴﺚ ﺑﻠﻎ ﻣﻌﺪل اﻟﺤﺪوث 53اﻻﻋﻤﺎر ﻓﻮق 
، آѧﺎن اﻏﻠﺒﻬѧﺎ ﻣѧﻦ %06ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ، ﺑﻠﻎ ﻣﻌﺪل اﻻﺻﺎﺑﺔ ﺑﺎﻟﻤﻀﺎﻋﻔﺎت ﻋﻠﻲ اﻟﺠﻬѧﺎز اﻟﻌѧﺼﺒﻲ 
اﻟѧﻀﻤﻮر اﻟﻌѧﺼﺒﻲ اﻟﻌѧﻀﻠﻲ اﻟﻨѧﺎﺗﺞ ﻋѧﻦ اﻟѧﺪاء . ع اﻟﺤѧﺴﻲ واﻟﺤﺮآѧﻲ ﻻﻟﺘﻬѧﺎب اﻟﻌѧﺼﺐ اﻟﻄﺮﻓѧﻲاﻟﻨѧﻮ
  % .8اﻟﺴﻜﺮي ﻣﺜﻞ 
ﻣﻦ ﻧﺘﺎﺋﺞ هѧﺬﻩ اﻟﺪراﺳѧﺔ اﺳѧﺘﻨﺒﻂ ﺑѧﺎن هﻨѧﺎك ﻋﻼﻗѧﺔ واﺿѧﺤﺔ ﺑѧﻴﻦ ﺣѧﺪوث اﻟﻤѧﻀﺎﻋﻔﺎت اﻟﺘѧﻲ ﻳѧﺼﻴﺐ 
اﻟﺠﻬﺎز اﻟﻌﺼﺒﻲ ﻟﻤﺮﺿﻲ اﻟﺪاء اﻟﺴﻜﺮي و اﻟﻌﻤѧﺮ وﻓﺘѧﺮة اﻻﺻѧﺎﺑﺔ ﺑﺎﻟѧﺴﻜﺮ وﻃﺮﻳﻘѧﺔ اﻟѧﺘﺤﻜﻢ ﺑﺎﻟѧﺴﻜﺮ 
  .ﻟﺪمﻓﻲ ا
ﻣѧѧﻦ اﻟﺤѧѧﺎﻻت اﻟﻤѧѧﺼﺎﺑﺔ ﻣѧѧﻦ ﻣѧѧﻮاﻃﻨﻲ ﻗﺒﺎﺋѧѧﻞ ﺷѧѧﻤﺎل اﻟѧѧﺴﻮدان، وان % 06آﻤѧѧﺎ اﻧѧѧﻪ ﻗѧѧﺪ ﻟѧѧﻮﺣﻆ ﺑѧѧﺎن 
ﻣѧﻦ اﻟﺤѧﻼت ﻳﻜѧﻮن ﻣѧﺼﺎﺑﺔ ﺑﺎﻟѧﺴﻜﺮ % 4.87ﻣѧﻦ اﻟﺤѧﻼت ﻣѧﻦ اﻟﻨѧﻮع اﻻول ﻟﻠѧﺴﻜﺮ، وان % 7.38
  .ﻻآﺜﺮ ﻣﻦ ﻋﺎم
ﻣѧﻦ اﻟﺤѧﺎﻻت % 82آﻤﺎ اﻧﻪ ﻗﺪ ﻟﻮﺣﻆ اﻳﻀﺎ ﺑѧﺎن ﻣѧﺮض ارﺗﻔѧﺎع ﺿѧﻐﻂ اﻟѧﺪم آѧﺎن ﻣѧﺼﺎﺣﺒﺎ ﻟﺤѧﻮاﻟﻲ 
  .    ﺔاﻟﻤﺼﺎﺑ
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Introduction and literature review 
Definition: 
     Diabetes mellitus, D.M is the most common endocrine disease with 
spectrum of syndromes, characterized by chronic hyperglycemia that is 
due to insulin deficiency, resistance or both1. It is usually irreversible and 
characterized by long term complications involving the eyes, skin, 
kidneys, nerves and blood vessels2. 
     Each point in the spectrum is associated with an absolute or relative 
deficiency of insulin coupled with varying degree of peripheral resistance 
to the actions of insulin. 
     It affects more than 30 million people world-wide3 .Diabetes is usually 
irreversible and although diabetic patients can have reasonable life-style, 
but its late complications results in reduced life expectancy and 
considerable uptake of health resources because macrovascular disease 
leads to an increased prevalence of coronary artery disease, peripheral 
 vascular disease and stroke also, microvascular damage causes diabetic 
retinopathy, nephropathy, and contributes to diabetic neuropathy3. 
Epidemiology: 
 
 
    
 
 
     Diabetes is world-wide in distribution and the incidence of both 
primary diabetes i.e. insulin dependant IDDM and type 2 D.M is 
increasing4. It affects more than 30 million people world-wide3. 
Pathophysiology:                                                                                                             
The metabolism of carbohydrate, fat and protein substrate is disturbed in 
diabetes. The osmotic diuresis of glucosuria carries Na, K, Ca and 
magnesium out of the body, so that the mineral balance is also disturbed. 
However the cationic loss is much greater if ketonuria is present because 
acetoacetate and 3-hydroxybuterate are relatively strong acids for those 
organic compounds hence 1 mole of ketoacid will be accompanied by 1 
mole of monovalent cations even at maximum urinary acidity4.  
A. Carbohydrates metabolism:- 
The organs most closely involved in blood glucose control are the liver, 
pancreas and the muscle. Disease of any of these may impair the glucose 
tolerance, but sustained glycaemic elevation always implies some failure 
of insulin secretion. The main action of insulin in this respect is the 
inhibition of hepatic glucose release and effectively gluconeogensis. The 
liver takes up excess glucose from the gut as the meal is digested and 
stores it as glycogen or uses the resulting acetyl CoA, not only for 
oxidation and energy production but also for fatty acid synthesis. This 
increases blood triglycerides and other lipids when blood glucose drops in 
2 
    
 the systemic hepatic artery blood. The liver releases glucose in the short 
term by glycogenolysis, and in the longer term by gluconeogensis and 
sparing of the hepatic carbohydrates by using triglycerides as the 
principal source of hepatic acetyl CoA for energy. The glycaemic level is 
also affected by rate of glucose removal in the peripheries; this may be 
either insulin dependant or independent. When there is gross insulin 
deficiency net protein degradation in muscle increases markedly and the 
plasma concentration of all amino acids increases. Hepatic 
gluconeogensis occurs from phosphoenol-pyruvate generated via malate 
and not directly from acetyl CoA. Hence non-esterified fatty acids are not 
substrate for gluconeogensis. In health high glucose concentration should 
be accompanied by high insulin levels. Insulin can be regarded as an 
agent that facilitates glucose entry into the sensitive tissues at any glucose 
level .Insulin is the key hormone involved in the storage and controlled 
release, within the body of the chemical energy available from food.  
     After secretion, insulin enters the portal circulation. It is carried to the 
liver, which is the prime target organ in which about 50% of the secreted 
insulin is extracted and degraded, and the residue is broken in the 
kidneys. Blood glucose levels are closely related in health and rarely stray 
out the range of 3.5-8.0 mmol/L despite the varying demand of food, 
fasting and exercise5.  
 
3 
    
     About 200gm of glucose is produced and utilized each day by the 
body. More than 90% is derived from the liver glycogen and hepatic 
 gluconeogensis; the remainder is from renal gluconeogensis. The brain is 
the major consumer of glucose .Its requirement of glucose is 1mg /kg 
body weight per minute. Glucose uptake by the brain is obligatory and is 
not dependant on insulin. Other tissues such as muscle and fat are 
facultative glucose consumer. The effect of insulin peaks, associated with 
lower threshold for glucose entry into the cells, is largely met by fatty 
acid oxidation. Glucose taken up by the muscles is stored as glycogen or 
broken down to lactate which renters with the circulation and becomes an 
important substrate for hepatic glucose production.  
B. Actions of insulin: 
               Insulin has profound effects on the metabolism of 
carbohydrates, fats, proteins and electrolytes. These can be divided into 
anabolic and anti-catabolic actions. The balance of these effects in the 
fasting and post-prandial states, and during exercise is controlled by: 
1- Variation in the relative circulating concentration of insulin, the only 
anabolic hormone, and several catabolic hormones namely glucagons, 
growth hormone, cortisol, catecholamine and thyroid hormones.  
2- The fact that insulin exerts its anti-catabolic effect at a lower 
concentration than that is required for it is anabolic action.  
 
4 
    
During oral glucose tolerance test or mixed meal, the first one and half 
hours are dominated by increasing secretion of insulin and inhibition of 
glucagons while cortisol and adrenalin levels are not changed. Exercise 
represents special stress with rapid increase in the demand for metabolic 
fuel. At rest 90 % of the energy requirement of the muscle comes from 
fatty acids and ketone bodies. 
     When the concentration of glucose in the plasma exceeds the renal 
threshold (that is the capacity of the renal tubules to reabsorb glucose 
from the glomerular filtrate) glycosuria occurs. The renal threshold is 
approximately10 mmol/L (182mg/dl), but there is a wide individual 
variation. Note that the severity of the classical symptoms of diabetes 
namely the polyuria and the polydipsia are related directly to the degree 
of glycosuria. If glycosuria develops slowly over many months or even 
years, as in NIDDM, the renal threshold for glucose rises and the 
symptoms of diabetes are correspondingly slight. This is one reason for 
the large number of undetected cases of NIDDM. Such individuals may 
have significant but symptomless hperglycaemia for many years before 
glucosuria is noted on routine urine testing .Sometimes they eventually 
present with symptoms due to one or more of the complications of long 
term diabetes which are: 
Parasthesia, pain, muscle atrophy in the legs, and impotence due to 
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neuropathy, or ulceration of the feet due to combination of neuropathy, 
 peripheral vascular disease, and infections or pulmonary tuberculosis or 
poor healing of wounds following surgery.  
A minority of cases of diabetes present for the first time as severe 
ketoacidosis either associated with an acute infection or other illness or 
even without precipitating cause in such cases abdominal pain and 
vomiting may be the presenting complaint. This is more likely to occur in 
IDDM. Diabetic ketoacidosis must therefore come in the differential 
diagnosis for patients who complain of acute abdominal symptoms. 
Classification: 
     Diabetes is a systemic disorder of energy metabolism. The central  
feature of the disease is hperglycaemia  secondary to a lack  of  insulin ,  
cellular  resistance , or a combination  of both . There are two main types 
of diabetes, type 1 and type 2. Type1 diabetes accounts for approximately 
10% of all affected patients and is due to destruction of βcells in the  
 pancreas with loss of insulin secretion and in turn insulin deficiency. 
Type2 diabetes represents about 90% of all cases and is due a 
combination of genetic factors that lead to insulin resistance and insulin 
deficiency. Type2 diabetes is commonly associated with increasing age, 
obesity, and central adiposity, sedentary life style and high caloric intake. 
 
6 
 The most common neurological complications of   both types of diabetes 
mellitus are diabetic neuropathy. Diabetic neuropathy is a syndrome 
    
comprising a series of separate clinical disorders that affects distinct 
component of the peripheral nervous system. The most common type of 
diabetic neuropathy is distal symmetrical sensori-motor polyneuropathy6   
Four major types of diabetes mellitus are recognized: type 1, type 2, 
gestational, and a class of other specific types .Terms such as juvenile 
onset, maturity onset diabetes of youth (MODY), insulin dependant, non 
insulin dependant have been deleted from the classification1.  
Type1 Diabetes mellitus:  
Type1 Diabetes mellitus results from cell-mediated autoimmune 
destruction of the beta cells of the islets of Langerhan,s of the pancreas. 
Circulatory markers of this destruction are autoantibodies to insulin, islets 
cells, glutamic acid decarboxylase (GAD), and several tyrosine 
phosphatases .One or more of these auto-antibodies are present in 85-90% 
of the newly diagnosed patient with type1disease. The disorder is 
strongly associated with HLA system, and influenced by the linkages to 
the DQA and DQB genes and DRB genes, these HLA DQ, DR alleles can 
be either predisposing or protective. Non-genetic factors also play a role 
since concordance for type1 in monozygotic twins is less than 50%.           
     The rate of beta cell destruction is variable; usually it is rapid in 
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 children and slower in adults. Keto-acidosis may be the first 
manifestation in young patients whereas in others modest hyperglycemia 
progresses, and in severe stress such as acute infection, Keto-acidosis 
    
develop. Type1 patients are prone to other autoimmune disorders such as 
Graves’s disease, Hashimotos thyroiditis, and pernicious anemia. 
Small subset of cases of type1 diabetes mellitus that do not have an 
autoimmune basis are classified as idiopathic type1 diabetes. This form of 
D.M is strongly inherited and lacks any evidence for an immunological 
process or HLA association. Most of these patients are of Asians or 
Africans.  
Type2DM:  
     Type2 diabetes mellitus is a heterogeneous disorder characterized by a 
degree of insulin resistance and a defect in insulin secretion by beta cells. 
More than 80% of patients with diabetes mellitus in the United States 
have type 2 diabetes mellitus which has strong genetic basis, as 
concordance among monozygotic twins is almost 100%. Affected 
patients have a 25% probability of having an affected parent. Although 
the genes responsible for type2 diabetes have not been isolated, it is likely 
that with the completion of the human genome project many patients now 
classified as type 2 will be included in the categories of genetic defects of 
beta cell function or genetic defect in insulin function. A note worthy  
 
8 
example of this concept is the disorder formerly referred to maturity onset 
diabetes of youth (MODY) four forms of this autosomal dominant 
monogenic defect in the beta cell function have identified and related to 
genetic mutations in the hepatocyte nuclear factors, an insulin promoting 
    
factor and transcription factor .Although these forms of diabetes are 
present in late adolescence or early adulthood circulating antibodies to 
GAD, and insulin are not present. Differentiating between type1and type2 
is sometimes difficult. There are 0growing numbers of African 
Americans who presents with Keto acidosis and appear to have classical 
type1diabetes, but after a short period turn to type2 without need for 
insulin. Obesity, hypertension, dyslipidemia characterized by elevated 
triglyceride and low HDL cholesterol are common concomitants of type2 
diabetes. The disorder is continuously progressive after fasting 
hyperglycemia develops and insulin deficiency starts 30-40% of patients 
require exogenous insulin eventually to control their glycemia. Screening 
for type 2 diabetes is not justified unless there is a high risk patient with a 
family history of the disease, obesity and hypertension. There increasing 
incidence of type 2diabetesin young persons. 
Gestational Diabetes GD: 
     It refers to glucose intolerance that is detected during Pregnancy. 
There is a wide diversity of opinion about the detection and management 
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 of gestational diabetes, but there is strong indication maternal 
hyperglycemia is a risk factor for both the mother and the fetus. Although 
screening of all pregnant women between 24 and 28 weeks of gestation 
has been recommended women at low risk include those younger than 25 
years without diabetes in first degree relative with a normal pregnancy 
    
weight and with no prior history of poor obstetrical outcome. Women at 
high risk of gestational diabetes may warrant screening early in 
pregnancy and include women with marked obesity diabetes in first 
degree relative. Clinical risk of gestational diabetes include increased 
frequency of  
pre-eclampsia in the mother and increased frequency of congenital 
abnormalities in the fetus. Women with gestational diabetes have 17% -
63% risk of developing diabetes within 5 to 6 years after the pregnancy. 
Weight gain and additional pregnancies increase the risk of gestational 
DM.   
Diagnosis:  
     The Expert Committee that established this classification also 
developed diagnostic criteria Expert Committee. Fasting plasma glucose 
is the recommended diagnostic test and the oral glucose tolerance test is 
no longer recommended for the routine use. A fasting glucose 
concentration of 110 - 125 mg/dl (6.1 - 6.9 mmol/l) is considered 
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 impaired fasting glucose which suggest a susceptibility to develop 
diabetes analogues to the (impaired glucose tolerance) of the older 
classification system. These lowered values reflect an effort to facilitate 
earlier diagnosis and to prevent complications7.   
Treatment:  
    
Treatment of type 1 diabetes mellitus:  
     Intensive insulin treatment of all patients with type1 should attempt to 
simulate the normal patter of insulin secretion (American Diabetes 
Association, ADA) NPH, lente, or ultralente insulin are used to provide 
basal insulin levels that in non-diabetic person regulate glucose levels 
during night and in between the meals. Regular and lispro insulin are 
administered before meals modulate the expected post prandial rise in 
glucose concentration and simulate the post prandial secretion of insulin 
characteristic of non-diabetic persons. Injections of NPH or lente insulin 
at bed time are intended to control fasting glucose level , these insulin 
counter the early morning rise in glucose concentration (the dawn 
phenomenon) that are the result of hepatic gluconeogensis. Pre-breakfast 
injection of NPH or lente insulin controls glucose level between meals. 
Most patients require three or more injections of insulin daily to achieve 
glycemic control.   
     Absorption of carbohydrates occurs in distal part of the small intestine 
and colon. The thaizolidinediones enhance insulin sensitivity by in 
11 
 creasing the expression of glucose transporters this action mediated after 
the agents bind to novel receptors, the peroxisome proliferators-activated 
receptors (PPAR-y). The results of the DCCT indicate that haemoglobin 
A1c value in the 7.2% - 8% and a mean plasma concentration of 5mg/dl 
(8.6mmol/l)? significantly reduce the appearance and the progression of 
micro vascular complications8.  
    
     If diet and exercise fail to control glycemia mono-therapy with a 
sulfonylurea or metformin is recommended .Both agents equally lower 
plasma glucose concentration, but because metformin promotes weight 
loss and lower plasma lipid concentration, it is preferred for obese 
patients. Dosage is increased every 4 to 8 weeks until fasting and post-
prandial glucose levels are decreased. If after several months, plasma 
glucose and postprandial hemoglobin A1c levels continue to be elevated, 
second oral agent should be added and its dosage escalated according to 
glucose levels. 
     Each of thiazolidines (troglitazone, rosiglitazone, and pioglitazone) 
increases sensitivity to insulin. Troglitazone has less effect on fasting 
plasma glucose and hemoglobin A1 levels than the sulfonylureas or 
metformin severe liver toxicity resulting in 61 reported deaths prompted 
the FDA and the manufacturer to withdraw troglitazone – are available as 
monotherapy or for combination with other oral agents or insulin9. Liver 
function tests should be done before initiation of therapy with any the  
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glitazones, and should be repeated every 2 months thereafter during the 
first years. If the serum alanine amino transferase is more than 50% above 
the upper limit of normal, glitazone should not be prescribed, or should 
be discontinued if treatment was started earlier. Among the adverse effect 
attributed to the thiazolidinediones are decreases in hemoglobin and 
hematocrit levels, mild edema and hypoglycemia when the agents are 
used in combination with insulin or other oral hypoglycemic compounds. 
    
Insulin therapy for type 2 diabetes: 
     An alternative to combination therapy with two oral agents is the 
combination of a single oral agent with bedtime intermediate-acting 
insulin, the dosage of bedtime insulin is adjusted according to the fasting 
plasma glucose level of the previous 5 days, with an objective of fasting 
levels in the 100 - 120 mg /dl range.  
Increments in dosage to achieve that goal are made every 5 to 7 days. 
Combination therapy of bedtime insulin and metformin is reported to 
achieve glycemic control without weight gain10. 
     For the symptomatic patient with type 2 diabetes whose plasma 
glucose levels exceed 280mg/dl, insulin rapidly reduces symptoms. Often 
after 6 to 8 weeks of improved glycemic control, such patients can be 
switched to on oral agent or the dosage of insulin reduced. Some 
asymptomatic patients who recognize the progressive nature of type  
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2diabetes and the relationship of hyperglycemia to complications choose 
insulin as their initial treatment. Intensive glycaemic control by multiple 
insulin injections delayed the onset of diabetic retinopathy, nephropathy, 
and neuropathy in Japanese patients11. From this study the glycaemic 
threshold to prevent the progression of microangiopathy is indicated as 
follows: HbA1c <6.5% FBG < 110 mg/dl and postprandial blood glucose 
<180 mg/dl.  Similarly, woman whose gestational diabetes is not 
controlled by diet should receive insulin to achieve the appropriate 
glycemic control during pregnancy. 
    
Complications of diabetes mellitus:  
1. Acute Complications: 
     Acute Diabetic Keto-Acidosis (DKA) and Hyperosmolar Non-ketotic 
Coma (HNC) are the major acute complications of the hyperglycemic 
syndromes. DKA is more common in type 1 diabetes, whereas HNC is 
more common in elderly patients with type 2 diabetes: however, there is 
overlap in the age distribution and in the metabolic spectrum of the two 
entities. 
Diabetic ketoacidosis (DKA):  
     The most common precipitants of DKA are infection (30%), none 
adherence to treatment (25%), and newly discovered diabetes (25%)12. 
Although increased, the plasma osmolality usually less than 320 mosm/kg 
H2O, while the anion gap exceeds 16 mg/l. The magnitude of the  
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hyperosmolality and of the anion gap relates to the degree of dehydration 
and the concentration of the extracellular fluid volume. The treatment 
plan for DKA must consider the degree of dehydration, the magnitude of 
the anion gap, and the arterial blood pH. Patients with hyperglycemia but 
with a plasma osmolality less than 320 mosm/kgH2O and an arterial 
blood pH >7.30 usually do not require hospitalization and can be treated 
in the emergency department on a short term basis where as patients with 
a pH less than <7.2 should be admitted for intensive treatment. In other 
patients, factors such as co-morbidity and home environment are 
determinants of the site of treatment. Insulin, saline and potassium are the 
    
main stay of emergency treatment of DKA, bicarbonate and phosphate 
are needed only in unusual circumstances. Intravenous insulin and saline 
are started immediately after the diagnosis is confirmed. A bolus of 
regular insulin 5-10 units followed by intravenous infusion at the rate of 
0.1 U / kg per hour is administered to reduce plasma glucose 
concentration by 75-100mg/dl per hour, often during the first 2 or 3 hours 
the fall is great. Saline is infused at a rate of 1-2 liters/ hour depending on 
the degree of volume depletion and the patient’s cardiovascular status. 
When plasma glucose levels decrease to 200 - 250 mg/dl range, 0.45% 
saline in 5% glucose can replace the original saline infusion and the 
insulin infusion adjusted to maintain that level. Provided that there is an 
 
15 
output of urine and the serum potassium is not above 5.0meq/L, 10 - 30 
meq/hr of potassium should be administered to maintain potassium level 
above 3.5meq/L. In patients with established diabetic nephropathy, the 
serum potassium must be measured every 2 hours. Bicarbonate is 
administered only in instances of severe acidosis (arterial pH<7.0).  In 
such cases 50 - 100 meq of bicarbonate should be given over 60 minutes 
period to increase pH to 7.1- 7.2.  Potassium phosphate can be 
administered if the serum phosphate has fallen below1.0 mg/L or there 
are clinical signs of hypophosphatemia as rhabdomyolysis, haemolysis, or 
unexpected left ventricular failure.  
    
When the patient feels well enough to eat, a single dose of regular insulin 
should be given subcutaneously 30 minutes to I hour before the insulin 
infusion is discontinued. Failure to administer the subcutaneous dose of 
insulin assures the return of hyperglycemia and ketonemia. Newly 
diagnosed patients should be started on NPH or lente insulin the day after 
ketoacidosis resolves. Established patients should return to their pre-
hospital insulin regimen. Prevention of recurrence is achieved by teaching 
the principles of insulin treatment, glucose and ketone monitoring, and 
early management if the patient feels sick. 
     Six potential complications may develop during the treatment of 
ketoacidosis: Accelerated coagulopathy, cerebral edema, hyperchloremic  
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acidosis, hypokalemia, hypophosphatemia, and hypoglycemia. Severe 
dehydration causes decreased perfusion of vital tissues and promotes 
coagulation processes that can result in organ infarction. 
Immediate infusion of normal saline and/or colloids restores circulatory 
function.  Urine output may also limit the effects of accelerated 
coagulation. Symptomatic cerebral edema occurs mostly in children and 
adolescents. Its pathophysiology is poorly understood and why life 
threatening cerebral edema does not occur in adults is uncertain. If within 
2 to 24 hours after treatment of DKA is initiated, headache, diminished 
consciousness, and then progressive neurological deterioration occur. 
Severe cerebral edema must be suspected and intravenous manitol should 
be administered immediately. Hyperchloremic acidosis from therapy is 
    
the result of excessive administration of high chloride-containing fluid, 
the increased urinary loss of ketones, and the intracellular accumulation 
of bicarbonate. Therapy for DKA shifts potassium form the extracellular 
to the intracellular space to achieve success is correcting sodium 
depletion. Insulin transports potassium as it stimulates glycogen 
synthesis. As a consequence, hypokalemia may develop. In the elderly, 
the threshold for thirst diminishes, or there may be a limited access 
intracellular hyperosmolarity, a hypotonic solution should be infused at 
the rate of 1 to 2 L/h. In older patients and in patients with cardiovascular  
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disease, central venous pressure should be monitored. Correction of 
hypovolaemia takes priority over all other considerations, but an   
evaluation should be done for such correctable precipitating factors as 
infection. Insulin doses similar to those used for DKA are effective when 
given after fluid therapy has been started. Potassium can be administered 
at the rate of 20 meq/h if serum potassium is <5.0 meq/l, but serum 
potassium should be measured every 2 to 4 hours. 
2. Chronic Complications of diabetes mellitus:  
A. Diabetic Retinopathy: 
     Diabetic retinopathy is the leading cause of new blindness among 
adults. The incidence of blindness is 25 times higher in diabetic patients 
than in the general population. There are three types of diabetic 
retinopathy: 
    
1- Non-proliferative  
2- Pre-proliferative, 
3- Proliferative.  
During the non-proliferative phase occlusion, dilatation, and increase 
of the small retinal vessels produce micro aneurysms that are detected 
on direct ophthalmoscopy. Micro aneurysms by themselves are not a 
threat to vision and ultimately most of these micro aneurysms 
disappear. However, the number of these micro aneurysms is an 
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 important predictor of the progression of diabetic retinopathy. If there 
is leakage of the serous fluid and lipoprotein in the area of the macula, 
macular edema can occur and central vision will be compromised. 
Presence of macular edema can be suspected if there are hard exudates 
in proximity to the macula, so prompt referral to ophthalmologist 
should be made. Loss of vision associated with macular edema can be 
reduced by 50% with laser photocoagulation.                                     
     Cotton wool spots (soft exudates) are ischemic infarcts of the inner 
layer of the retina and represent advanced form of retinopathy. These may 
be accompanied by beading of the retinal vein or tortuous retinal 
capillaries, and indicate that pre-proliferative retinopathy is present and 
the patient should be referred to the ophthalmologist for further 
evaluation. Neovascularization of the surface of the retina some times 
extends into the posterior vitreous and is the most vision threatening stage 
    
of retinopathy. New vessels are prone to bleed, and if bleeding occurs in 
the vitreous the patient reports floaters or cobwebs. Major retinal 
hemorrhage is the cause of sudden painless blindness. Proliferation of the 
fibrous tissue leads to retinal detachment as the fibrous tissue contracts. 
In both type 1 and type2 D.M, intensive control of glycemia reduces the 
risk of developing retinopathy and slows its progression13. However the 
prevalence of retinopathy increases progressively with the increase 
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 duration of the disease. Retinopathy begins to occur 3 to 5 years after 
diagnosis in patients with type 1diabetes and within 15to 20 years of 
having the disease all patients have some retinopathy. The natural history 
of diabetic retinopathy differs in patients who are 70 years or older at the 
time of diagnosis. The prevalence of retinopathy is much less in younger 
patients due to haemodynamic, hormonal, and biochemical factors.   
B. Lipoprotein A (Lpa) and apolipoprotein A (Apo a): 
Micro-albuminuric patients have lipoprotein A levels significantly greater 
than normo-albuminuric patients, and normo-albuminuric patients show 
higher (Lpa) levels than controls. Patients with retinopathy or neuropathy 
show similar (Lpa) levels to those with out retinopathy or neuropathy. No 
differences I (Apo a) isoforms frequencies were observed between 
subgroups with and without complications. However, among patients 
with retinopathy, those with proliferative retinopathy had higher (Lp a) 
levels and a different (Apo a) isoforms distribution than those with non-
    
proliferative and background retinopathy. The above mentioned data 
suggest that young type 1 diabetic patients without micro-albuminuria 
have (Lpa) levels higher than healthy subjects of the same age. (Lpa) 
levels are further increased in micro-albuminuric patients. High (Lpa) 
levels and (Apo a) isoforms seems to be associated with presence of 
proliferative retinopathy, but have no relation to neuropathy14 
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C. DIABETIC NEPHROPATHY:   
     Is the most common cause of end stage renal disease. 20-30% of 
patients with diabetes develop evidence of nephropathy. A smaller 
fraction of those with type 2 diabetes progress to end stage renal disease, 
yet because of the great prevalence of type2 disease, such patients 
constitutes 50% of diabetic patients receiving dialysis. The Diabetes 
Control and Complication Trial, the United Kingdom prospective 
Diabetes Study, the Stockholm Intervention Study, and the Kumamoto 
study all show that the onset and the course of nephropathy can be 
significantly affected by several intervention, provided that these are 
made very early15. Incipient nephropathy presents with micro-
albuminuria of 30 mg/day. Without intervention, an increase in urine 
albumin at the rate of 10-20% is almost universally accompanied by 
hypertension. After overt nephropathy (>300mg of albumin/day) occurs, 
the glomerular filtration rate falls relentlessly at a rate of 1ml/min per 
month. A higher proportion of patients with type2 diabetes have micro- 
    
albuminuria shortly after diagnosis than in patients with type1 disease 
because diabetes has frequently been present for many years before 
diagnosis and / or albuminuria may reflect a disease other than diabetes. 
In type1 and type2 diabetes, albuminuria is a marker for cardiovascular 
mortality and morbidity. Cardiovascular complications are four to eight  
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folds higher in diabetic patients with renal disease than without renal 
disease. 
     A urinalysis should be done annually in all patients with type 
2diabetes; if protein is absent, then a test for micro-albuminuria should be 
done. Patients with type1diabetes need not to be tested before puberty or 
for 5years after the onset of the disease. Measurements of albumin to 
creatine ratio in a random urine sample is the easiest test in the office 
setting; however 24urine collection allows the simultaneous measurement 
of the creatine clearance. Four interventions reduce the risk of developing 
micro-albuminuria and overt nephropathy:  
1-Glycemic control, 
2- Control of hypertension,  
3- Use of anti hypertensive agents, and 
4- Protein restriction.  
     Intensive therapy of type1 and type2 diabetes significantly reduces the 
risk of micro-albuminuria and overt nephropathy. 
    
Both systolic and diastolic hypertension accelerate the progression of 
diabetic nephropathy, and aggressive treatment designed to decrease and 
maintain systolic blood pressure below 130 mmHg, and diastolic pressure 
below 85 mmHg decreases the rate of fall of the glomerular filtration rate. 
The United Kingdom study confirms that when blood pressure is 
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intensively treated to maintain levels less than 144/82mmHg, significant 
reductions in strokes, heart failure, progression of micro-angiopathic 
complications, and visual loss can be anticipated. 
Angiotensin-Converting Enzyme (ACE) inhibitor therapy reduces 
microalbuminuria even in normo-tensive persons and slows the rate of 
progression of renal disease in type1 diabetes. In the United Kingdom 
study, β-blockers and ACE inhibitors were equally effective in lowering 
the blood pressure and reducing the incidence of micro-albuminuria and 
proteinuria. 
A meta-analysis examining dietary protein restriction of 0.5- o.8/ kg per 
day suggests beneficial effect on glomerular filtration rate, creatinine 
clearance, and albuminuria. The American Diabetes Association 
recommends dietary protein of 0.8gm/kg wt per day. 
D. Diabetic Foot Problems: 
     More than 50% of all none trauma amputations in the United States 
are attributable to diabetes. Foot lesions are frequently the cause of 
amputations and are usually the result of a combination of peripheral 
    
neuropathy, peripheral vascular disease, and superimposed infection. Feet 
that are insensitive, deformed, and /or ischemic are susceptible to trauma, 
ulceration, infection, and gangrene. The pathogenesis of the diabetic foot 
begins with loss of pain sensation that is often accompanied with loss of 
vibratory sensation and results in a deformed foot due to tendon  
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shortening. The deformed foot with “hammer toes” causes redistribution 
of weight-bearing, which promotes the developing of foot ulcers. When 
such ulcers develop in the setting of peripheral vascular insufficiency, 
amputation is a predictable consequence. 
Distal symmetric polyneuropathy is an important predictor of ulcers and 
amputations. Controlling plasma glucose and cessation of smoking delay 
neuropathy and reduce the risk of vascular disease. Neuropathic ulcers in 
the diabetic foot go undetected because they are usually painless. Painful 
distal foot lesions usually indicate peripheral vascular insufficiency is 
accompanied by diminished or absent pulses, dependant rubor, and pallor 
on elevation. 
Non-invasive Doppler techniques can determine the extent of the vascular 
disease.  
 E. Neuropathic Complication: 
The   pathogenesis of diabetic neuropathy: 
     The pathogenesis of diabetic neuropathy is multiple. In addition to the 
vascular lesions and segmental demyelination there are abnormalities of 
both axoplasmic transport and the mechanism generating the action 
    
current and perhaps also the nodal membranes? One hypothesis is 
proposed to explain Schwann cell and myelin abnormalities is the 
excessive entry of glucose into the glucose 6 phosphate pathway, with the 
resulting increase in sorbitol . This sugar alcohol largely remains where it  
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is formed for example within the ocular lens or Schwann cell. The high 
sorbitol content of the peripheral nerves is not in doubt and one argument 
for the involvement of sorbitol is slightly improved peripheral nerve 
conduction in animals with experimental diabetes given aldolase 
reductase, lens opacities in animals can also be partially reversed by such 
inhibitor. The sorbitol excess hypothesis established in terms of inisitol 
deficiency for the former leads to the latter. Inisitol is essential for 
phosphoinositide synthesis and formation of diacyl glycerol which is 
important activator of protein kinase C. increased glycosylation of myelin 
is another potential pathogenic process.    
     A sensorimotor neuropathy characterized by conduction deficits and 
increased F waves and cord dorsum potential latencies was present in 
both pelvic and thoracic limbs and except in the most severely affected 
animals occurred with little or no electromicrograpgic abnormality. As 
for nerve structural abnormalities, Schwann cell injury was prevalent and 
included myelin defects such as splitting, ballooning and demyelination, 
although axonal degeneration was noted in biopsies from severely 
affected cats. Evidence of polyol pathway activity consisted of marked 
increases in nerve fructose without appreciable sorbitol accumulation. 
    
Tricyclic antidepressants, Carbamazepine and phenytoin have been used 
with variable improvement of the pain and sleep interference16. 
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CLASSIFICATION:                                                                      
1. Somatic  sensory neuropathy :  
     Involved both large fibers such as those serving modalities of joint 
position, vibration, and that contribute to touch. Small fibers which serve 
as pain temperature sensor as well as contributing to touch. This type of 
neuropathy is almost always symmetrical and affects both arms and legs, 
but the latter predominantly. It is responsible for the loss of tendon jerks 
first at the ankle.     
2. Mononeuropathy:   
     Can result from pressure palsy or from vascular accident to a nerve. 
Both motor and sensory are unduly vulnerable to pressure in diabetes. 
Occasionally clinical episodes occur that suggest stroke affecting a 
peripheral nerve, but more commonly the onset is insidious. If biopsy or 
post mortem specimen s are examined microscopically, obstruction of the 
vasa nervosum is common in this condition particular with either femoral 
neuropathy or palsy of the third cranial nerve. Mononeuropathy may be 
multiple giving the clinical picture mononeuritis multiplex with 
interruption of more than one peripheral nerve trunk otherwise seen in 
disorders such as polyarteritis nodosa or sarcoidosis.                                    
3. Motor neuropathy:   
    
     Affects proximal nerves asymmetrically and usually involves part of 
the femoral plexus. Some clinicians believe that this is special example of   
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mononeuropathy, but it may be too wide spread, to make this likely.  
4. Autonomic Neuropathy: 
     In the developed world, diabetes is the most common cause of 
neuropathy. Symmetric neuropathy occurs in both the upper and lower 
extremities, but is more common in the lower extremities. Symptomatic 
parasthesia of ‘pins and needles’, often more severe at night, are the most 
common frequent clinical presentation. Hypoesthesia develops and places 
patients at risk for trauma and foot ulcers. Less common but more 
annoying to the patient is painful neuropathy that affect the knees and 
ankles and to lesser extent the lower extremities below the knee and the 
upper extremities. Gabapentin, an anticonvulsant, appears to be 
efficacious for the pain and sleep disturbance Associated with painful 
diabetic neuropathy. Tricyclic antidepressant, carpamazepine and 
phenytoin have been used with variable improvement of the pain and 
sleep interference 16. 
     The autonomic neuropathies of diabetes usually present in concert 
with peripheral neuropathy and include impaired cardiovascular reflexes 
that result in orthostatic hypotension and an increased heart rate, gastro 
paresis, diabetic diarrhea, neurogenic bladder, and impotence in males. 
Orthostatic hypotension can be alleviated by treatment with 
    
fludrocortisone, although it causes sodium and water retention and must 
be used cautiously in patients with cardiac or renal disease. 
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Metoclopromide benefits patients with gastro paresis who experience 
early satiety, nausea, vomiting, and abdominal discomfort secondary to 
delayed gastric emptying. Diabetic diarrhea is often most marked. 
F. Diabetic Cataract:  
     Premature cataract occur in diabetic patients and seen to correlate with 
both duration of diabetes and the severity of hyperglycemia. Non 
enzymatic glycosylation of the lens protein is twice as high in diabetic 
patients as in age matched nondiabetic persons and may contribute to 
premature occurrence of cataracts (25). Diabetes accelerates the 
formation of senile cataract. And rarely snowflake cataract may develop 
rapidly during the period of very poor glycaemic control at any age (Cecil 
text book of medicine 21 edition).  
G. Diabetic retinopathy: 
     Up to 20% of patients with type 2 diabetes have retinopathy at the 
time of diagnosis. Vision threatening retinopathy never appears in type 1 
patient in the first 3-5 years of diabetes. Annual consultation with 
ophthalmologist should be arranged for patients who have had type1 
diabetes for more than 3-5 years, and for all patients with type 2 diabetes, 
because many were probably diabetic for an extensive period of time 
before diagnosis 25. 
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H. Diabetic neuropathy: 
     Symptomatic disabling neuropathy affects nearly 50 % of diabetic 
patients .It is usually symmetrical, but could be focal, and often involve  
the autonomic nervous system as well. The prevalence of symmetrical 
neuropathy is similar in type1 and type2 diabetes mellitus where as focal 
neuropathy is more common in older type 2patients nerve growth factor 
in the nerves of patients with neuropathy, perhaps limiting the 
regenerative capacity. Nerve bundles and ganglia from type 1diabetic 
patients with autonomic neuropathy, show monocytic infiltration and 
their sera may contain complement fixing antibodies suggesting that 
autoimmune mechanism may also contribute to this complication. 
Because the mechanisms producing such a heterogeneous clinical picture 
are poorly understood, neuropathy is classified according to the area 
affected as follows:  
Polyneuropathy, mononeuropathy, distal symmetrical                                   
isolated peripheral nerve lesion, chronic sensori-motor,                              
cranial, acute sensory, radiculopathy, proximal motor, 
Autonomic neuropathy and distal sensorimotor neuropathy 
This syndrome characterized by axonal loss is the most common 
manifestation of diabetes mellitus distal neuropathy the process involves 
all somatic nerves, but has distinct predilection to distal sites, e.g. feet and 
hands .Symptoms characteristically worsens. 
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Diabetes can affect the nervous system in several ways. 
Of all the neurological complications of diabetes, 
peripheral neuropathy is by far the commonest and has 
been extensively studied. The involvement of central 
nervous system can be in several forms. The underlying 
damage may be due to involvement of the large and small 
cerebral blood vessels as also due to metabolic 
derangement caused by prolonged hypoglycemia, anoxia 
or ketoacidosis. The neurological emergencies that occur 
in diabetes can be:  
 1) Atherothrombotic and lacunar strokes;  
 2) Convulsive disorder in the setting of both hypo and 
hyperglycemia;  
3) Coma;   
4) Cranial neuropathies; and   
5) Acute proximal muscle weakness.   
     In patients with diabetes, atherothrombotic stroke is 
associated with poor outcome. Hyperglycemia at the time 
of stroke is an important risk factor for an adverse 
    
outcome than chronic stable diabetic state. Proper 
management of diabetes in these acute situations is 
crucial for a better outcome of the underlying disease 
process 19.  
     Posterior column lesions were more common than 
corticospinal tract involvement.  
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     All patients had combined peripheral sensory 
polyneuropathy with myelopathic signs. The combination 
of peripheral neuropathy, disturbed sense of position 
and/or vibration with pyramidal signs is highly suggestive 
of diabetic myelopathy with polyneuropathy. Even though 
myelopathy is not common in diabetic patients, it is one of 
the most debilitating neurological complications of 
diabetes mellitus. There is enough pathological and clinical 
evidence to accept the concept 20.  
     An acute neuropathy rarely occurs early in the course 
of diabetes mellitus. In spite of their occurrence shortly 
after beginning insulin therapy, the role of treatment with 
insulin in the onset is uncertain. 21. 
Symmetrical distal diabetic neuropathy was a common 
complication of diabetes mellitus 22.  
    
     Subclinical diabetic neuropathy is common. Early 
diagnosis is important for possible prevention of late 
neuropathic complications (foot ulcers and infections). 
Prolonged poorly controlled diabetes mellitus, old age and 
smoking are risk factors for symptomatic diabetic 
neuropathy. Meticulous blood glucose control is important 
for nerve function protection. Researches are urgently 
needed for satisfactory therapy. 23. 
     Diabetes mellitus was present in 11.4 per cent of 684 patients with 
Bell's palsy, in 28.4 per cent of the sixty-seven with recurrent or bilateral 
palsy, and in 16.8 percent of the 440 with palsy who were thirty years or  
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older. Diabetes was present in only 3.8 per cent of 27,399 persons thirty  
years or older who had never had Bell's palsy and who underwent 
multiphasic health testing. These figures clearly indicate that diabetes is 
more common among patients with Bell's palsy than among persons who 
have never had that disease; and that the risk of Bell's palsy is increased 
in patients with diabetes. The diabetic patient is more prone than the non-
diabetic person to nerve degeneration, and this tendency to nerve 
degeneration is not age-related. Although 10 per cent of our patients with 
Bell's palsy and known diabetes were younger than thirty-nine years, we 
now advise screening for blood sugar elevation only for patients who are 
forty years or older, or who have recurrent or bilateral facial paralysis. 24.  
    
Data from the clinical charts of 44 diabetic patients with 
oculomotor palsy were studied. The sixth cranial nerve 
was involved in 55 p. 100 of cases, the third in 39 p. 100 
and the fourth in 6 p. 100 of cases. Forty three patients 
had type II diabetes mellitus; in 19 the oculomotor palsy 
revealed diabetes, while in 25 patient’s diabetes mellitus 
had been diagnosed for 9.5 +/- 6.2 years. The oculomotor 
palsy resolved within an average of 93 days on average 
(range 156-39 days). Twenty eight patients had arterial 
hypertension and 23 ischemic cardiopathy of peripheral 
arteriopathy. There appeared to be no correlation between 
oculomotor palsy and the quality of glycemia control, 
renal function, the presence of 
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 diabetic retinopathy, or other diabetic neurological 
complications 25, 26 and 27. 
     One of the hallmarks of diabetes mellitus is its 
propensity to cause neurological complications. Diabetes 
is an independent risk factor of stroke. Diabetic 
neuropathy represents the most common type of 
peripheral neuropathy in our country. Improved glucose 
control can improve nerve function and restoration of the 
    
euglycemic state appears to stop the progression of the 
neuropathy. Treatment strategy of painful neuropathy 
with tricyclic antidepressant, anticonvulsant, anesthesia 
agents and topical capsaicin is discussed 28. 
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OBJECTIVES  
 
     To study prevalence and clinical pattern of neurological   
complications among Sudanese diabetic patients in Al Shaab 
Teaching Hospital.  
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PATIENTS & METHODS 
METHODOLOGY: 
# Study design:  Descriptive cross sectional. 
# Study field: Al Shaab Teaching Hospital, STH, Department of 
neurology. 
#Study population:  patients with diabetes mellitus in Al Shaab 
and Khartoum teaching Hospital from   Jan 2003 – Oct 2004.  
    
 # Inclusion criteria: Sudanese adult patients with diabetes 
mellitus. 
#Exclusion criteria:  Patients below 15 years of age.  
# Sampling:  
• Sample size: 100 patients. 
• Sample    design: Systemic random sample. 
• Sample frame: List by registration number. 
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# Tools of data collection: 
   Data were collected by:  
1- Pre-design questionnaire. 
2- Clinical examination. 
3- Investigations. 
#Data entry and analysis: 
    
Data was introduced into the computer from a master sheet 
recording using S.P.S.S.  Software program, data were entered 
and analyzed using the student t-test.  
*Age was grouped into: 15-24, 25 –34, 35-44, 45 –54, 55-64, 
and >65. 
*Residence was classified as: 
Khartoum state, central, west, east, north and south. 
#  Symptoms: Polyuria, polydipsia, weight loss, itching, cough, 
diarrhea, sweating, palpitation, chest pain, seizures, cranial 
nerves, and impotence. 
2. Physical examination was grouped into;  
General, systemic and neurological examinations. 
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2A. Neurological examinations were further arranged into: 
Higher mental function, cranial nerves, upper limbs, trunk, and 
lower limbs. 
4. Work   up as:     
  General and specific investigations.  
    
4A.The specific investigations:  
Imaging, CSF, NCS, and EMG.      
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Table1: Showed that patients of age group distribution 15-24 to 
be 9%. 25-34 to be 6% 35-44, 10%. 45-54      , 25%.55-64, 
21%.and more than 65 years 29%.    
    
Table2: showed the duration of diabetes in years, 0-4, 31 
patients. 5-9, 23 patients. 10-14, 11 patients. 
Table3: showed that 62% of the patients are males and 38% are 
females.  
Table 4: : showed that 76% of the patients are resident in 
Khartoum, 12%in central, 5% in the north, 4% in the east, and 
3% in the west. 
neuropathy, while 40% showed no neuropathy. 
Table 5: : showed that polyuria was found in 79% polydipsia 
in78%, weight loss was found in 62%.Itching was found in 22% 
of patients, diarrhea was found in 24% of patients. Sweating was 
found in 24% of patients, cranial nerve lesions were found in 
12% of patients. Palpitations in 19% of patients.21% had 
numbness, impotence in 5%, and urinary symptoms were found 
in 5% of patients. 
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Table 6: showed that 60%of the patients reported to have 
diabetic  neuropathy, while 40% showed no neuropathy . 
Table 7: showed that 31 patients was reported symmetrical 
mainly sensory – motor polyneuropathy( distal), diabetic 
    
amyotrophy was reported in  9 patients , autonomic neuropathy, 
and  mono neuropathy 16 patients. 
Table8: showed that 16  patients had mononeuropathy14 
showed cranial nerve lesions, 2 showed isolated  peripheral 
nerve lesion. 
Table 9: showed that 8 % of diabetic patients had proximal 
myopathy , while 92% showed no evidence of proximal 
myopathy. 
Table 10: showed that 9% of patients  had diabetic amyotrophy 
,while 91% had no diabetic amyotrophy. 
Table 11: showed that 19   % of patients had diabetic  retinopthy 
while 81% had no diabetic retinopthy. 
 Table 12: showed that 11% had simple background retinopthy, 
7% had proliferative retinopthy, while1% had maculopathy. 
Table 13: showed that 14 patients  had cataract . 
38 
 
Table 14: showed that 19  patients  had  othoer neurological 
complications, 13 with hemiplegia, 4 patients with paraplegia, 2 
patients epilepsy. 
Table 15: showed that 2 patients  had  mononeuritismultiplex. 
    
Table 16: : showed that 28% of the patients were found to have 
coexisting hypertention, while 72%had no hypertention. 
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Figure1: Showed that patients of age group distribution 15-24 to 
be 9%. 25-34 to be 6% 35-44, 10%. 45-54      , 25%.55-64, 
21%.and more than 65 years 29%.    
    
Figure 2: showed that 62% of patients are male, and 38% are 
female. 
Figure 3: showed that 75% patients are married,while14% 
bachilor ,6% widow and 4% divorce.  
Figure 4: showed that polyuria was found in 80%,  while 
20%had no polyuria. 
Figure 5: : showed that 14.6% had cranial nerve affections , 
while 85.4% had no cranial never affections. 
Figure 6: : showed that 19% had type1 diabetes mellitus,78% 
had type2 , 2% gestational diabetes and 1% secondary diabetes. 
Figure 7: showed  87 % on regular treatment, while 13% was 
found to be not on regular treatment36 % on oral hypoglycemic, 
37% on insulin 13 % on diet and 1% combination treatment.                 
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TABLE1:- -  Age distribution among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital    
                         :  
  
Number of patients Age group  
9 15-24  
6 25 –34  
10 35-44  
25 45 –54  
    
21 55 –64  
29       >65   
100 Total 
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TABLE 2:- - Duration of diabetes among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
  
 
 
Number of patients  Duration in years  
31  
  
0-4  
23  5-9  
  
11                   10-14  
  
35                      15>  
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TABLE 3:- - Sex distribution among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
                              
  
  
 
62 
 
MALE 
 
38 
 
FEMALE 
100 
 
TOTAL 
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  TABLE4:Residence distribution among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital    
                     
  
  
76 KHARTOUM 
12 CENTRAL 
5 NORTHEN  
4 EASTREN 
3 WESTERN 
100 TOTAL 
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TABLE 5:- Clinical presenting symptoms among 100 Sudanese 
patients seen in EL shaab teaching Hospital  
            
80 POLYURIA 
77 POLYDEPSI 
62 WEIGHT LOSS 
21 ITCHING 
17 COUGH 
24 DIARRHEA 
24 SWEATING 
19 PALPITATION 
17 CHEST PAIN 
12 SEIZURES 
12 CRAN IAL NERVES 
21 NUMBNESS 
04 DIZZNESS 
05 IMPOTENCE 
04 ABDOMINAL PAIN 
    
02 URINE RETENTION 
03 URINE INCONTINENCE 
39 OTHERS 
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TABLE 6 Prevalence  of neuropathy among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
  
  
  
WITHOUT 
NEUROPATHY  
WITH NEUROPTHY 
                       
TOTAL  
40  60  100  
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TABLE 7:-Types of neuropathy among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital                              
   
  
MONO 
NUROPATHY 
AUTONOMIC 
NEUROPATHY 
DIABETIC 
AMYOTROPHY 
SENSORY -
MOTOR  
16  9  8  31  
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TABLE 8 Distribution of mono- neuropathy among 100 
Sudanese diabetic patients seen in EL shaab Teaching Hospital   
  
  
  
PERIPHERAL NERVES  CRANIAL NERVE 
AFFECTION  
TOTAL  
2  14  16  
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TABLE 9:- Prevalence of myopathy among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
  
  
  
WITHOUT MYOPATHY WITH MYOPATHY TOTAL 
92 8 100 
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TABLE 10:- Prevalence of diabetic amyotrophy among 100 
Sudanese diabetic patients seen in EL shaab Teaching Hospital  
    
   
WITHOUT WITH DIABETIC 
AMYOTROPHY 
TOTAL 
91 9 1OO 
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TABLE 11:- Prevalence of retinopathy among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
  
  
  
WITHOUT 
RETINOPATHY 
WITH DIABETIC 
RETINOPATHY 
TOTAL 
81 19 100 
–  
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 TABLE 12:- Types of retinopathy among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
  
  
  
       
MACULOPATHY PROLIFERATIVE 
RETINOPATHY 
SIMPLE 
BACKGROUND 
RETINOPATHY 
TOTAL 
1  7  11  19    
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TABLE 13:- Prevalence of cataract among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
    
      
  
WITHOUT WITH  CATARCT TOTAL 
86  14 I00 
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TABLE 14:- Prevalence of other neurological manifestations 
among 100 Sudanese diabetic patients seen in EL shaab 
Teaching Hospital  
      
        
  
EPILEPSY HEMIPLEGIA PARAPLEGIA TOTAL 
2 13 4 19 
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TABLE 15 :- Prevalence of mono- neuritis multiplex among 100 
Sudanese diabetic patients seen in EL shaab Teaching Hospital  
   
  
  
WITHOUT WITH MONO NEURITI 
MULTIPLEX 
TOTAL 
98  2  100  
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TABLE 16:- Prevalence of hypertension among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
  
  
  
DIABETICS WITHOUT 
HYPERTENSION 
DIABETICS AND 
HYPERTENSIVES 
TOTAL 
72 28 100 
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Figure 1: - Age distribution among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
  
AGE
AGE
>6555-6445-5435-4425-3415-24
P
er
ce
nt
%
40
30
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Figure 2: - Sex distribution among 100 Sudanese diabetic   
  
patients seen in EL shaab Teaching Hospital  
  
  
  
SEX
62 62.0
38 38.0
100 100.0
male
female
Total
Frequency Percent
  
  
  
  
  
SEX
38.0%
62.0%
female
male
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Figure 3:- The Marital Status among 100 Sudanese diabetic patients 
seen in EL shaab Teaching Hospital  
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Figure 4:- Frequency of polyuria among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
  
POLYURIA
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80.0%
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POLYURIA
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20 20.0
100 100.0
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Frequency Percent
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Figure 5:- Frequency of cranial nerve involvement among 100 
Sudanese diabetic patients seen in EL shaab Teaching Hospital  
  
Pie 
Chart
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Frequency Percent
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
61 
  
Figure 6:- Types of diabetes among 100 Sudanese diabetic 
patients seen in EL shaab Teaching Hospital  
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Figure 7:- Types of treatment of diabetes among 100 Sudanese 
diabetic patients seen in EL shaab Teaching Hospital  
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DISCUSSION 
    
     The study was carried out to see the prevelence of 
neurological complications among  Sudanese patients attending 
Elshab teaching hospital. 9% of cases of the study lie in the age 
group15-24, 6%in the age group 24-34, 10% in the age group 
35-44, 25% in the age group 45-54, 21% in the age group55-64, 
and 29% their age more than 65 years. In conclusion more than 
85% of patients are above 35years of age while 15% of patients 
are below 35years. 56% of patients lie in the age group35-64%. 
Males (62%) were females 38% fig.1.The majority of patients 
from Khartoum state and the surroundings (76%) followed by 
the central states (12%), the north states, (5%), the east states 
(4%), the west states(3%). This can be explained by migration 
towards Khartoum and the war in the south but no significant 
geographical etiological factor is suspected.  
Family history of diabetes was reported in (76%) of patients, 
and this shows that it has significant value. Polyuria was found 
in 80% of patients and polydipsia in78%, weight loss was found 
64 
 in 62% of the patients, sphincteric disturbance was found in 5% 
of the patients, while bowl disturbance was found in 5% of the 
patients. Diabetic neuropathy was found in 60% of patients, 
    
which is mainly distal symmetrical peripheral neuropathy found 
in 31 patients which constitute the main neurological 
complication of diabetes mellitus. Diabetic amyotrophy was 
found in 8 patients out of 60 patients with neuropathy. 
Autonomic neuropathy was found in 9 patients. 
Mononeuropathy was found in 16 patients, 14 of them showed 
cranial nerve lesions, while 2 only isolated peripheral nerve 
lesion. 
Other neurological complications as hemiplegia were found in 
13 patients, paraplegia in 4 patients and epilepsy in 2 patients. 
Diabetic retinopathy was found in 19 patients. 11 of them were 
found to have simple background retinopathy, 7 suffered from 
proliferative retinopathy. Only one patient was found to have 
maculopathy. 
Cataract was found in 14 patients, Table 13. 
 
65 
Hypertention has been found to coexist in 28% of patients. 
Most of the patients with peripheral neuropathy either motor, 
sensory or mixed ; have duration of D.M (more than 7 year . 
also it is associted with poor glycamic contorl.the  
    
 The rest of neurolog ical complications  were also correlated 
with the duration and poor glycamic contorl.2% of our study 
group have epilepsy which can be one of the neurolog ical 
complications either through the endo-neural capillary 
microangiopathy or superadded infection. 
------------------------------------------------------------        
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CONCLUSION & RECOMMENDATIONS   
  
CONCLUSION   
 
o In this study, male to female ratio were 1.63:1, and most of 
the patients from Khartoum state and central states. 
o Polyuria, polydipsia and weight loss were the main 
presenting complaints in most of the patients. 
o Of all neurological complication of diabetes, peripheral 
neuropathy is by far the commonest complication. 
o There was a significant positive correlation between the age, 
duration of diabetes, glycaemic control and the occurrence of 
neurological complication.  
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RECOMMENDATIONS 
 
It is important for the diabetics to be diagnosed and treated  
as early as possible to decrease the incidence of neurological 
complication,  and to prevent progression to severe neuropathic 
complication by means of optimal glycemic control. 
Diabetic patients should be examined regularly looking for  
evidence of neurological complications. 
 In any patient with peripheral neuropathy diabetes should be excluded.  
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